Bayer and Novartis to debut new data at ASH 2015
pharmafile | November 30, 2015 | News story | Research and Development, Sales and Marketing | American Society of Hematology, Bayer, Conference, Novartis, ash, clinical trials, haematology, oncology
Pharma firms will present clinical trial results for the pipeline drugs they are pinning their 2016 hopes for success on, at the American Society of Haematology annual meeting in Orlando on December 5-8.
Bayer will present 11 abstracts demonstrating the latest pre-clinical and clinical data from its oncology and haematology development pipeline at the meeting.
Bayer’s oncology pipeline includes three marketed products and several other compounds in various stages of clinical development. The haematology pipeline includes compounds in various stages of development for haemophilia, sickle cell anaemia, thalassemia and other blood and bleeding disorders.
The company says that “these portfolios and pipelines reflect the company’s commitment to delivering science for a better life, prioritising specific targets for intervention with the potential to improve the way that cancer and rare blood and bleeding disorders are treated.”
“We are excited to present the latest data from our expanding haematology and oncology pipelines, as they demonstrate our scientific leadership in bleeding disorders and cancer research,” says Dr David Weinreich, Bayer’s head of global development for specialty medicine.
Their pharma rivals Novartis will highlight data for drugs for blood cancers, including leukaemias, lymphomas and myelomas, as well as supportive care, rare and difficult-to-treat cancers, and personalised cell therapies.
In a example that may bear fruit in 2016, Novartis and the University of Pennsylvania’s Perelman School of Medicine have an exclusive global collaboration to research, develop and commercialise chimeric antigen receptor CAR-T cell therapies for the investigational treatment of cancers. The Swiss firm will present new data on investigational CAR-T therapy CTL019, as well as new research for pipeline compound ABL001, a small molecule that could potentially treat chronic myeloid leukaemia.
Novartis will also present clinical data for its existing oncology drugs Jakavi (ruxolitinib), Tasigna (nilotinib) and Farydak (panobinostat). In addition, Sandoz, the arm of Novartis that produces generics and biosimilars, will present data from PROTECT 2, one of its pivotal Phase III trials investigating their proposed pegfilgrastim biosimilar in patients with chemotherapy-induced neutropenia.
Bruno Strigini, who is president of Novartis Oncology, says: “We pride ourselves in our drive for new science and innovation, and look forward to bringing this promise to life at ASH through the results of our latest haematology research. We will be presenting encouraging overall survival data for both investigational and approved products, underscoring our commitment to improve and extend people’s lives.”
Lilian Anekwe
Related Content
Bayer and Evotec to collaborate on precision cardiology
Bayer and Evotec have announced that they have updated the focus of their collaboration to …
PeptiDream and Novartis extend peptide discovery collaboration
PeptiDream has announced the expansion of its peptide discovery collaboration with Novartis Pharma AG.
Novartis shares new data about Fabhalta for IgAN treatment
Novartis has announced new results from a pre-specified interim analysis of its phase 3 APPLAUSE-IgAN …
